多発性硬化症治療薬の世界市場および研究開発展望2016-2026

◆英語タイトル:Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
◆商品コード:VGAIN60619
◆発行会社(調査会社):visiongain
◆発行日:2016年6月
◆ページ数:151
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、多発性硬化症治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. 多発性硬化症の概要

3. 主要な多発性硬化症治療薬

4. 多発性硬化症治療薬パイプライン 2016-2026

5. 多発性硬化症治療薬の世界市場 2016-2026

6. 主要な治療セグメント: 収益見通し 2016-2026

7. MS治療薬の国別市場: 収益見通し 2016-2026

8. 研究・分析の結論
【レポートの概要】

MS Drugs – Discover R&D Trends and Markets with Highest Revenue Potentials
Where is the multiple sclerosis drugs market heading? Visiongain’s new study predicts that pharma industry’s revenues from 2016. There you find potentials for sales growth, also exploring trends, technologies, patients’ needs and opportunities.

Our report gives you revenue forecasts to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data. Instead see what is happening for those central nervous system (CNS) drugs, hearing how you can gain in knowledge and benefit your influence.

Please read on to explore those therapies and discover what revenue their future market could generate.

Forecasts to 2026 and other analysis show you commercial prospects
Besides revenue forecasting to 2026, our new study shows you historical and epidemiological data, growth rates and market shares. See progress in products and clinical trials, exploring what the future holds. And you get 81 tables and 48 charts.

With our study you assess trends, demands and sales potentials for MS-treating medicines. You see, from 2016, where needs and money exist. Discover the most lucrative market segments and products, including conventional drugs and biologics.

The following sections explain how you benefit from our new investigation.

Forecasts from 2016 for the world MS medicines market and submarkets
What are the secrets of that industry’s progress? See expected trends there. Along with prediction of the overall world market for treating multiple sclerosis, our report shows you revenue forecasting of five therapeutic submarkets to 2026 at world level:
• Monoclonal antibodies (mAbs)
• S1PR modulators
• Interferons
• Other immunomodulators
• Other agents.

Our analyses and discussions show you commercial potentials for MS-treating medicines, present and future. Discover those opportunities for improved treatment.

With our study you get the forecasting leaders need, benefiting your authority. Our study’s purpose is to help your research, analyses and decisions.

There, in our work, you also find revenue predictions for leading products.

Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026: Revenue Forecasts for Leading Submarkets including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif

Predictions of leading products’ sales – what is possible for those CNS drugs?
How will individual multiple sclerosis medicines perform to 2026 at world level? Our new report shows revenue forecasts to 2026 for 10 leading marketed drugs and three promising candidates in the R&D pipeline:
• Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
• Tecfidera (dimethyl fumarate) by Biogen
• Avonex (interferon beta-1a) by Biogen
• Gilenya (fingolimod) by Novartis
• Rebif (interferon beta-1a) by Merck KGaA
• Tysabri (natalizumab) by Biogen
• Betaseron/Betaferon (interferon beta-1b) by Bayer
• Aubagio (teriflunomide) by Sanofi
• Plegridy (peginterferon beta-1a) by Biogen
• Lemtrada (alemtuzumab) by Sanofi
• Ocrelizumab (Ocrevus / RG1594) by Roche
• Ozanimod by Celgene
• Zinbryta (daclizumab high-yield process) by Biogen and AbbVie.

In our study you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, exploring challenges, trends, competitors and opportunities.

Discover what the future holds for treating multiple sclerosis. Our work also shows you geographical predictions by leading country.

National and regional markets – what outlooks for demand and sales?
In developed and developing countries, opportunities for MS drug developers and producers will occur from 2016, leading to revenue gains. Find the most promising markets.

Our investigation shows revenue forecasts to 2026 for 10 leading national markets for multiple sclerosis drugs:
• US
• Japan
• Canada
• Germany, France, UK, Italy and Spain
• India and China.

There you explore progress and outlooks. You assess that those medicines’ future – hear about developments, also finding their meaning and sales potentials.

That way you find opportunity and assess challenges. Our work explains what the future holds, exploring issues affecting those pharmaceutical companies.

Forces affecting MS drug producers and the healthcare needs they serve
Our report shows you activities, developments and events affecting that industry and market from 2016, including these influences:
• Demographics and geographical distribution
• Prevalence and incidence of multiple sclerosis
• Disease modifying treatments
• Immunomodulators, monoclonal antibodies, S1PR modulation and other drug classes on the market and in development
• Challenges from generics and biosimilars
• Patent protection and regulatory affairs.

With our survey you explore political, economic, social and technological questions, assessing outlooks for business. You examine forces stimulating and restraining that pharmaceutical market.

You also assess the most promising aspects of that industry’s research and development. Discover what that pharma sector’s present and future hold.

Leading companies and overall 2020 market value – how high can sales go?
What is possible there? Our analysis predicts the overall world market for MS drugs will reach $23.2 billion in 2020. It will show revenue expansion from 2016 to 2026, giving companies high commercial potentials.

In particular our study explores activities, capabilities and results of these firms:
• Biogen
• Teva Pharmaceutical Industries
• Novartis
• Merck KGaA
• Bayer
• Sanofi
• Roche
• Celgene.

In our work you assess companies’ results, strengths and outlooks. So discover where that industry heads, helping you stay ahead in knowledge and succeed.

5 main ways Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026 helps – gain data found nowhere else
Our new investigation helps you in these five main ways, benefiting your research, plans, decisions and presentations:
• Revenues to 2026 for MS drugs at overall world level – explore commercial potentials for companies, their drug development and products
• Prospects of 5 therapeutic submarkets and 13 drugs to 2026 – discover the revenue generating potentials of existing and expected MS medicines
• Forecasts to 2026 for 10 national markets in North America, Europe and Asia – investigate developed and developing countries’ revenue potentials
• Outlooks for established and rising MS drug companies – assess portfolios, results and prospects of developers, producers and marketers
• Analysis of what stimulates and restrains that large, expanding pharma market – explore that segment’s trends, helping you compete and succeed.

That report, by our in-house analysts in the UK, could benefit your reputation for knowledge, helping you succeed. Gain analysis leading companies depend on.

Data found nowhere else, helping your research, assessments and planning
Our new report gives you independent analysis. You receive business intelligence found only in our work. With that study you are less likely to fall behind in data or miss opportunity. Instead discover what the future holds for your business.

That way discover where prospects and money exist. Our investigation’s purpose is to benefit your research, analysis and decisions, also saving you time and effort.

Prospects for drugs treating multiple sclerosis – explore that market’s future
Our new study is for everyone investigating the potential of existing and new CNS drugs. There, for MS, you find revenue forecasting from 2016, seeing trends, progress and discussions. Avoid missing out – please get our report here now.

【レポートの目次】

1. Report Overview
1.1 Multiple Sclerosis Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Multiple Sclerosis
2.1 What is Multiple Sclerosis?
2.1.1 Key Statistics: 2.5 Million Sufferers in the World
2.2 The Pathology of MS
2.2.1 Symptoms
2.3 Diagnosis of MS
2.3.1 Tests for MS Include These Technologies
2.4 Measuring MS
2.5 The Different Types of MS
2.5.1 Relapsing-Remitting MS (RRMS)
2.5.2 Secondary Progressive MS
2.5.3 Progressive Relapsing MS
2.5.4 Primary Progressive MS
2.5.5 Other Presentations of the Disease
2.6 Possible Causational Factors for MS
2.6.1 Genetic Factors
2.6.2 Infection
2.6.3 Environmental Factors and Less Well-Supported Theories
2.7 Demographics and Geographical Distribution
2.8 Different Treatments for MS

3. Leading Multiple Sclerosis Drugs
3.1 Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
3.1.1 First Non-Interferon Immunomodulator
3.1.2 Teva and the Approval of Generic Competition
3.1.3 The First Generic is Approved – Sandoz’s Glatopa
3.1.4 Industry Surprised by Copaxone’s Solid Sales, Despite Generic Competition: 40mg Dose is Key
3.1.5 Patents on Copaxone 40mg Being Contested – Although Teva Receives Good News in Europe
3.1.6 Copaxone Revenues 2011-2015
3.1.7 Copaxone Revenue Forecast 2016-2026
3.2 Tecfidera (dimethyl fumarate) by Biogen
3.2.1 Rapidly Grown Since 2013 to Become the Leading Oral MS Therapy
3.2.2 Tecfidera Revenues 2013-2015
3.2.3 Tecfidera Revenue Forecast 2016-2026
3.3 Avonex (interferon beta-1a) by Biogen
3.3.1 The Leading Interferon Therapy
3.3.2 Avonex Revenues 2011-2015
3.3.3 Patent Extension to 2026
3.3.4 Avonex Revenue Forecast 2016-2026
3.4 Gilenya (fingolimod) by Novartis
3.4.1 The First Oral Disease-Modifying Drug for MS
3.4.2 US Patent Trial and Appeal Board Sides Against Novartis
3.4.3 Gilenya Revenues 2011-2015
3.4.4 Gilenya Revenue Forecast 2016-2026
3.5 Rebif (interferon beta-1a) by Merck KGaA
3.5.1 Merck Attempting to Differentiate Rebif from Other Interferon Therapies
3.5.2 Rebif Revenues 2011-2015
3.5.3 Rebif Revenue Forecast 2016-2026
3.6 Tysabri (natalizumab) by Biogen
3.6.1 High Efficacy Offsets the Risks
3.6.2 Tysabri Revenues 2011-2015
3.6.3 Tysabri Revenue Forecast 2016-2026
3.7 Betaseron / Betaferon (interferon beta-1b) by Bayer
3.7.1 First Disease Modifying Drug for MS
3.7.2 Betaseron Revenues 2011-2015
3.7.3 Betaseron Revenue Forecast 2016-2026
3.8 Aubagio (teriflunomide) by Sanofi
3.8.1 More than 48,000 Patients Treated
3.8.2 Aubagio Revenues 2014-Q1 2016
3.8.3 Aubagio Revenue Forecast 2016-2026
3.9 Plegridy (peginterferon beta-1a) by Biogen
3.9.1 36% Reduction in ARR compared to Placebo
3.9.2 Plegridy Revenues 2014-2015
3.9.3 Plegridy Revenue Forecast 2016-2026
3.10 Lemtrada (alemtuzumab) by Sanofi
3.10.1 Very Effective, but with Side Effects
3.10.2 Lemtrada Past Revenues and Revenue Forecast 2016-2026

4. Multiple Sclerosis Drugs Pipeline 2016-2026
4.1 Ocrelizumab (Ocrevus / RG1594) by Roche
4.1.1 Humanised mAb Targeting CD20
4.1.2 First Drug to Receive Breakthrough Therapy Designation for MS
4.1.3 Exciting Latest Results from Two Phase 3 Trials
4.1.4 Ongoing Clinical Trials
4.1.5 Ocrelizumab Revenue Forecast 2016-2026
4.2 Ozanimod by Celgene
4.2.1 S1PR Modulator
4.2.2 Promising Results from Phase 2 RADIANCE Study
4.2.3 Ongoing Clinical Trials
4.2.4 Ozanimod in MS Revenue Forecast 2018-2026
4.3 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie
4.3.1 Humanised mAb Being Jointly Developed by two Giants
4.3.2 Positive Opinion on Marketing Authorisation from the CHMP
4.3.3 Zinbryta Revenue Forecast 2016-2026
4.4 Ofatumumab by Novartis
4.4.1 Novartis Acquires Full Remaining Rights in $1bn Agreement
4.4.2 Advantages and Disadvantages over Ocrelizumab
4.5 Ponesimod by Actelion
4.5.1 S1PR Modulator
4.5.2 Positive Earlier Results
4.6 Laquinimod by Teva and Active Biotech
4.6.1 Troubled Oral Immunomodulator
4.6.2 Turned Down for European Licence
4.7 MED1003 by MedDay
4.7.1 Unique Method of Action
4.7.2 Results from MS-SPI and MS-ON
4.8 Masitinib by AB Science: Phase 3 and has Completed a Futility Analysis
4.9 Siponimod (BAF312) by Novartis: Competitor for Gilenya

5. Global Multiple Sclerosis Drugs Market 2016-2026
5.1 Global Multiple Sclerosis Drugs Market Forecast 2016-2026
5.2 What Factors Will Drive Growth in the Global MS Drugs Market?
5.2.1 Growth of Existing Products, Reaching Peak Blockbuster Revenues before Patent Expiry
5.2.2 Exciting New Products Due to be Launched Within the Next Ten Years
5.2.3 Premium Prices, Accompanied by Price Increases
5.2.4 Prevalence and Incidence of Multiple Sclerosis is Increasing
5.2.5 Unmet Needs and Strategic Partnering
5.3 What Factors will Restrain Growth in the Global MS Drugs Market?
5.3.1 Multiple Patent Expiries on Leading Drugs will Lead to Generic and Biosimilar Competition
5.3.2 Declining Healthcare Budgets Could Lead to Cost Pressures
5.3.3 Crowded Marketplace

6. Leading Therapeutic Segments: Revenue Prospects, 2016-2026
6.1 The Main Therapeutic Segments within the MS Drugs Market, Forecast 2016-2026
6.2 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.3 Monoclonal Antibodies Segment Forecast 2016-2026
6.4 S1PR Modulator Segment Forecast 2016-2026
6.5 Interferons Segment Forecast 2016-2026
6.6 Other Immunomodulators Segment Forecast 2016-2026
6.7 ‘Others’ Segment Forecast 2016-2026

7. National Markets for MS Drugs: Revenue Prospects, 2016-2026
7.1 Multiple Sclerosis Cases and Prevalence Values
7.2 Leading Regional Markets Forecast 2016-2026
7.2.1 Regional Composition of the Market in 2015, 2020 and 2026
7.3 US MS Drugs Market
7.3.1 Reasons why the US Market Dominates the MS Drugs Market to Such an Extent
7.3.2 Undergoing Some Changes
7.3.3 US MS Drugs Market Forecast 2016-2026
7.4 EU5 MS Drugs Market 2016-2026
7.4.1 Common Characteristics of all the EU5 Nations in Regards to MS Drugs and Drivers of Growth
7.4.2 German MS Drugs Market: Leading EU Market
7.4.2.1 German MS Drugs Market Forecast 2016-2026
7.4.3 French MS Drugs Market: Strong Healthcare System
7.4.3.1 French MS Drugs Market Forecast 2016-2026
7.4.4 UK MS Drugs Market
7.4.4.1 UK MS Drugs Market Forecast 2016-2026
7.4.5 Italian MS Drugs Market
7.4.5.1 Italian MS Drugs Market Forecast 2016-2026
7.4.6 Spanish MS Drugs Market
7.4.6.1 Spanish MS Drugs Market Forecast 2016-2026
7.5 Canadian MS Drugs Market: Country has Highest Rate of MS in the World
7.5.1 Canadian MS Drugs Market Forecast 2016-2026
7.6 Japanese MS Drugs Market Forecast 2016-2026
7.7 Chinese MS Drugs Market Forecast 2016-2026
7.8 Indian MS Drugs Market Forecast 2016-2026

8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change?
8.3 How will National Markets Develop from 2016 to 2026?
8.4 Concluding Remarks

Table 2.1 The Kurtzke Expanded Disability Scales (EDSS)
Table 3.1 Total Copaxone Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.2 Copaxone Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.3 Copaxone Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.4 Total Tecfidera Revenues 2013-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.5 Tecfidera Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.6 Tecfidera Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.7 Total Avonex Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.8 Avonex Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.9 Avonex Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.10 Total Gilenya Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.11 Gilenya Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.12 Gilenya Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.13 Total Rebif Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.14 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.15 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.16 Total Tysabri Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.17 Tysabri Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.18 Tysabri Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.19 Total Betaseron Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.20 Betaseron Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.21 Betaseron Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.22 Total Aubagio Revenues 2014-2015, Revenues ($m), AGR (%)
Table 3.23 Aubagio Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.24 Aubagio Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.25 Total Plegridy Revenues 2014-2015, Revenues ($m), AGR (%)
Table 3.26 Plegridy Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.27 Plegridy Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 3.28 Total Lemtrada Revenues 2013-2015, Revenues ($m), AGR (%), CAGR (%)
Table 3.29 Lemtrada Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.30 Lemtrada Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 4.1 Ocrelizumab: Selected Ongoing Clinical Trials, 2016
Table 4.2 Ocrelizumab Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2020
Table 4.3 Ocrelizumab Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 4.4 Ozanimod: Selected Ongoing Clinical Trials, 2016
Table 4.5 Ozanimod Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2020
Table 4.6 Ozanimod Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 4.7 Zinbryta Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2020
Table 4.8 Zinbryta Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 4.9 Siponimod: Ongoing MS Clinical Trials, 2016
Table 5.1 Total MS Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 5.2 Total MS Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 5.3 Selected MS Drugs Achieving Peak Revenues During Forecast Period: Revenue ($m)
Table 6.1 Therapeutic Segments within the MS Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 6.2 Therapeutic Segments within the MS Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.3 Monoclonal Antibodies Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 6.4 Monoclonal Antibodies Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.5 S1PR Modulator Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 6.6 S1PR Modulator Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.7 Interferons Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 6.8 Interferons Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.9 Other Immunomodulators Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 6.10 Other Immunomodulators Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.11 ‘Others’ Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 6.12 ‘Others’ Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.1 Total Number of People with MS in the US, EU5, Canada, Japan, China and India, 2013
Table 7.2 Prevalence of MS within the Nations Forecasted in this Report: Population Size, Number of People with MS, Prevalence (%), 2013
Table 7.3 Regional Forecasts for the Global MS Drugs Market (US, EU5, Canada and Japan): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.4 Regional Forecasts for the Global MS Drugs Market (China, India, ROW and Total Global Market): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.5 Regional Forecasts for the Global MS Drugs Market (US, EU5, Canada and Japan): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.6 Regional Forecasts for the Global MS Drugs Market (China, India, ROW and Total Global Market): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.7 US MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.8 US MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.9 German MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.10 German MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.11 French MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.12 French MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.13 UK MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.14 UK MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.15 Italian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.16 Italian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.17 Spanish MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.18 Spanish MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.19 Canadian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.20 Canadian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.21 Japanese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.22 Japanese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.23 Chinese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.24 Chinese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 7.25 Indian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 7.26 Indian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026

Figure 3.1 Total Copaxone Revenues 2011-2015, Revenues ($m)
Figure 3.2 Copaxone Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.3 Total Tecfidera Revenues 2013-2015, Revenues ($m)
Figure 3.4 Tecfidera Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.5 Total Avonex Revenues 2011-2015, Revenues ($m),
Figure 3.6 Avonex Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.7 Total Gilenya Revenues 2011-2015, Revenues ($m),
Figure 3.8 Gilenya Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.9 Total Rebif Revenues 2011-2015, Revenues ($m)
Figure 3.10 Rebif Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.11 Total Tysabri Revenues 2011-2015, Revenues ($m)
Figure 3.12 Tysabri Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.13 Total Betaseron Revenues 2011-2015, Revenues ($m),
Figure 3.14 Betaseron Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.15 Aubagio Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.16 Plegridy Revenue Forecast: Revenue ($m), 2015-2026
Figure 3.17 Lemtrada Revenue Forecast: Revenue ($m), 2015-2026
Figure 4.1 Ocrelizumab Revenue Forecast: Revenue ($m), 2016-2026
Figure 4.2 Ozanimod Revenue Forecast: Revenue ($m), 2018-2026
Figure 4.3 Zinbryta Revenue Forecast: Revenue ($m), 2016-2026
Figure 5.1 Total MS Drugs Market Forecast: Revenue ($bn), 2015-2026
Figure 5.2 Total MS Drugs Market Forecast Broken Down by Therapeutic Segment (Line Graph): Revenue ($m), 2015-2026
Figure 6.1 Therapeutic Composition of the MS Drugs Market: Market Share (%), 2015
Figure 6.2 Therapeutic Composition of the MS Drugs Market: Market Share (%), 2020
Figure 6.3 Therapeutic Composition of the MS Drugs Market: Market Share (%), 2026
Figure 6.4 Monoclonal Antibodies Segment of the MS Drugs Market, Forecast: Revenues ($m),
2015-2026
Figure 6.5 S1PR Modulator Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
Figure 6.6 Interferons Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
Figure 6.7 Other Immunomodulators Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
Figure 6.8 ‘Others’ Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
Figure 7.1 Global MS Drugs Market by Region: Revenue ($m), 2015-2026
Figure 7.2 Regional Composition of the Global MS Drugs Market (Pie Chart): Revenues ($m), 2015
Figure 7.3 Regional Composition of the Global MS Drugs Market (Pie Chart): Revenues ($m), 2020
Figure 7.4 Regional Composition of the Global MS Drugs Market (Pie Chart): Revenues ($m), 2026
Figure 7.5 US MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.6 German MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.7 French MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.8 UK MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.9 Italian MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.10 Spanish MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.11 Canadian MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.12 Japanese MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.13 Chinese MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 7.14 Indian MS Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 8.1 Global MS Drugs Market Forecast: Revenues ($m), Annual Growth Rate (%), 2015-2026
Figure 8.2 Global MS Drugs Market Broken Down by Therapeutic Segment (Area Graph): Revenues ($m), 2015-2026
Figure 8.3 National Markets for MS Drugs (Bar Chart): Revenues ($m), 2015
Figure 8.4 National Markets for MS Drugs (Bar Chart): Revenues ($m), 2026

★調査レポート[多発性硬化症治療薬の世界市場および研究開発展望2016-2026]販売に関する免責事項
★調査レポート[多発性硬化症治療薬の世界市場および研究開発展望2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆